Melflufen for relapsed and refractory multiple myeloma.

Albert OriolAlessandra LaroccaXavier LeleuRoman HajekHani HassounPaula Rodríguez-OteroAgne PanerFredrik H SchjesvoldJoachim GullboPaul G Richardson

Published in: Expert opinion on investigational drugs (2020)

Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
acute myeloid leukemia
prognostic factors
diffuse large b cell lymphoma
single cell
hodgkin lymphoma
risk assessment
replacement therapy
smoking cessation